
|Articles|December 1, 2005
- Volume 0 0
FDA Reviews Trexima for Treatment of Migraines
Author(s)Susan Farley
Advertisement
GlaxoSmithKline and POZEN Inc announced that the drugTrexima will be reviewed by the FDA for the acute treatmentof migraine headaches. The companies have proposed Treximaas the brand name for their combination of sumatriptansuccinate (Imitrex) and naproxen sodium (Aleve, for example)in a single-tablet form. Pending approval by the FDA, Treximacould be available to the public by the second half of 2006.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Articles in this issue
almost 21 years ago
CAN YOU READ THESE Rxs?almost 21 years ago
Bar Coding Thwarts Illegitimate Drug Usealmost 21 years ago
COMPREHENSIVE CARE CLINIC: DIABETES: Diabetes-related Stress and Depressionalmost 21 years ago
Hypertension Counseling Requires a Multifactorial Approachalmost 21 years ago
COMPOUNDING HOTLINEalmost 21 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingalmost 21 years ago
EnterpriseRx Pharmacy Management Systemalmost 21 years ago
Hospital Installs Automated Medication Cabinetsalmost 21 years ago
"Smartphones" Help with Clinical Trial Informationalmost 21 years ago
HIT Needs Medicare's LeadershipAdvertisement
Related to this article

Technology empowers patients and optimizes medication use.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Safe storage and responsible disposal help protect patients from accidental poisoning and drug misuse while keeping medications stable and effective.

Preserving patient access requires attention to the people, workflows, and financial structures behind the pharmacy counter, not just the number of open pharmacy locations.

The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
When Medicine Changes Faster Than Health Care: Preparing for a New Era
4
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
5


